miR-137 acts as a tumor suppressor by suppressing B-cell lymphoma/leukemia 11A (BCL11A) expression, leading to the inhibition of CSCs’ self-renewal and proliferation ability, and shrinkage of the tumor mass. The gene discussed is BCL11A; the disease is neoplasm.